Marshall Wace LLP Sells 482,336 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Marshall Wace LLP decreased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 91.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,613 shares of the company’s stock after selling 482,336 shares during the period. Marshall Wace LLP owned 0.09% of Pacira BioSciences worth $803,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PCRX. Renaissance Technologies LLC lifted its stake in Pacira BioSciences by 0.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company’s stock valued at $37,541,000 after acquiring an additional 13,604 shares during the last quarter. Geode Capital Management LLC lifted its stake in Pacira BioSciences by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company’s stock valued at $20,578,000 after purchasing an additional 5,071 shares during the last quarter. Impax Asset Management Group plc grew its holdings in Pacira BioSciences by 14.8% during the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company’s stock worth $10,174,000 after purchasing an additional 69,424 shares during the period. Charles Schwab Investment Management Inc. increased its position in Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock worth $9,462,000 after buying an additional 70,307 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in Pacira BioSciences by 3.4% in the fourth quarter. Wellington Management Group LLP now owns 470,191 shares of the company’s stock valued at $8,858,000 after buying an additional 15,542 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PCRX shares. Barclays raised their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. HC Wainwright upped their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 8th. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $26.67.

Pacira BioSciences Trading Down 0.4 %

PCRX opened at $26.90 on Thursday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.24 billion, a PE ratio of -13.25 and a beta of 0.71. The company has a fifty day moving average of $24.58 and a 200-day moving average of $21.68. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.